Navigation Links
Helix BioPharma reports Q2 2008 highlights, financial results
Date:3/10/2008

ilings in the U.S. and Europe, respectively, in 2008.

Research and development expenditures related to the Phase II trial in Sweden are below the Company's original projections. This is attributable to a lower patient enrollment rate. Helix is currently in discussion with the regulatory authorities in Sweden as it relates to a protocol amendment put forth by the Company to restore the recruitment rate to the original projections that forecasted patient enrollment to be completed by the end of the 2008 calendar year. In order to achieve the enrollment completion timeline previously projected, the Company will have to expand the trial to other jurisdictions and multiple sites and, therefore, incur additional costs.

With the recent private placement, the Company is now in a better position to expedite the commercialization of its new drug candidates and expects research and development expenditures to increase in the latter half of fiscal 2008 and into fiscal 2009.

Operating, general & administration

Operating, general & administration expenses totaled $1,245,000 and $2,558,000, respectively, for the three and six month periods ended January 31, 2008, compared to $1,578,000 and $2,447,000, respectively for the same periods a year ago. Lower operating, general and administration expenses for the three month period ended January 31, 2008, were mainly the result of lower costs associated with the Company's annual shareholder meeting held on January 29, 2008. These costs were offset by additional costs incurred for wages, audit and consultancy services in the quarter.

For the six month period ended January 31, 2008, operating, general and administration expenses were marginally higher, with higher wages, audit and consultancy services along with a one-time charge in the first quarter of fiscal 2008 related to the resignation of the Company's then Chairman being partially offset by lower costs for the Company's annual shareholder meeting.
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 ... by Product (1D & 2D Gel Electrophoresis, Agarose & ... MEKC, Reagents, Informatics), by Application & by End User ... Electrophoresis Market is expected to reach around $1.98 Billion ... forecast period 2015 to 2020. Browse ...
(Date:5/21/2015)... 21, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... that develops and commercializes proprietary technologies and products for ... results for the second fiscal quarter ended March 31, ... continued to advance business with our existing customers and ... President and CEO of SQI. "The delivery of a ...
(Date:5/21/2015)...  Prima Biomed Ltd. (NASDAQ: PBMD ) a ... a leader in the development of immunotherapeutic products for ... CVac data from the Phase II CAN-003 ovarian cancer ... clinically meaningful improvement in Overall Survival ("OS") over standard ... In the group of second remission patients (n=20), the ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 W. ... its manufacturing facility in Worms, Germany has received ... independent subsidiary of the International Pharmaceutical Excipient Council ... facilities that produce its SYLOID® FP brand of ... GMP certification, following the Curtis Bay, Maryland (USA) ...
Breaking Biology Technology:Electrophoresis Market Worth $1.98 Billion by 2020 2Electrophoresis Market Worth $1.98 Billion by 2020 3Electrophoresis Market Worth $1.98 Billion by 2020 4SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Correction Continues after Big Move - BrokerBank Securities, Inc. 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2
... Fisher,Scientific Inc. (NYSE: TMO ) today ... a leading third-party logistics provider to the,pharmaceutical ... was previously majority-owned by Arsenal Capital,Partners. With ... Priority,Solutions offers a comprehensive range of services ...
... With a special eye for the,details hidden from casual ... G. Aspinall. Photographs of architectural details from beaches,to buildings ... fore. The,collection includes images from seven different countries., ... the,president of Genzyme Genetics, is also a talented artist ...
... - Biomira Inc. (Nasdaq: BIOM ),(TSX: BRA) ... Chief,Executive Officer, is scheduled to present at the ... EDT on Wednesday, October 10. The presentation ... be accessed at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=BIOM&item_id=1 ,657575 ...
Cached Biology Technology:Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services 2Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services 3Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services 4An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery 2
(Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... 2015 Research ... the addition of the  "5-year Opportunity ... Market"  report to their offering.  ,     ... analyses trends in the iris recognition ... sectors, globally. Despite hardware pricing and ...
(Date:5/19/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... group of leading UK scientists and social scientists led by the ... joined-up thinking on the emerging politics of plants. Green is ... of plants from food to fuel, industrial feedstocks to carbon ... cornerstone of the global economy. But such fame comes ...
... Feb. 24 BIO-key International, Inc. (OTC Bulletin Board: ... biometric identification solutions, today reported results for the fourth ... Company,s results reflected profitability for the fourth quarter and ... strong revenue growth for the quarter and the year. ...
... Damon Runyon Cancer Research Foundation named 13 new ... Award Committee review. The recipients of this ... basic and translational cancer research in the laboratories ... The Fellowship is specifically intended to encourage the ...
Cached Biology News:Plants are political hot potatoes 2BIO-key(R) Reports Profitability for Fourth Quarter and Full Year 2008 2BIO-key(R) Reports Profitability for Fourth Quarter and Full Year 2008 3BIO-key(R) Reports Profitability for Fourth Quarter and Full Year 2008 4BIO-key(R) Reports Profitability for Fourth Quarter and Full Year 2008 5BIO-key(R) Reports Profitability for Fourth Quarter and Full Year 2008 6Damon Runyon Cancer Research Foundation awards prestigious fellowships to 13 top young investigators 2Damon Runyon Cancer Research Foundation awards prestigious fellowships to 13 top young investigators 3Damon Runyon Cancer Research Foundation awards prestigious fellowships to 13 top young investigators 4